(Q74651627)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

0 references

M Moro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Y Inada

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M Kojima

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H Miyata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

H Komatsu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R Torii

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 February 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Pharmacology

12 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

57-66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

Clinical and Endocrinological Analyses of Patients with Galactorrhea and Menstrual Disorders due to Sulpiride or Metoclopramide

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Medical treatment of hyperprolactinaemic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Therapeutic applications of bromocriptine in endocrine and neurological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Mechanism of increased prolactin secretion by sulpiride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Effect of sulpiride on serum prolactin levels in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Adrenergic and Dopaminergic Modulation of Growth Hormone and Prolactin Secretion in Normal and Tumor-Bearing Human Pituitaries in Monolayer Culture*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Drugs five years later. Bromocriptine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

Influence of sulpiride-induced hyperprolactinemia on baboon menstrual cycles: a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900940-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(98)00940-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10096770%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference